1992 weighted average price increase for total product line will be "a little under 2%," company CEO William Steere tells April 23 annual shareholders' meeting. Pfizer received several new product approvals in 1991 and early 1992, which might account in part for the modest price increases. Steere also informed investors that Pfizer's Pratt Pharmaceuticals subsidiary had received 65,000 applications for 500 new sales positions.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth